Doug Fulling, MA, and Andrew Cournoyer, MBA, discuss how patients could benefit from payers learning more about a new drug by joining clinical trials earlier.
Doug Fulling, MA, president of Precision AQ, and Andrew Cournoyer, MBA, senior vice president and director of the access experience team, Precision AQ, spoke with The American Journal of Managed Care® about how introducing payers into clinical spaces earlier could benefit their patients.
This transcript has been lightly edited for clarity.
Transcript
How can patients benefit from payers being introduced into clinical trials earlier?
Doug Fulling: One of the big focuses in clinical research is to diversify the patient populations that actually participate in clinical research. And if you think about payers, they have access and exposure to those diverse patient populations. So by working closely with them during the clinical trial, we have the ability to focus on making sure that there's a true representation of the US population, for those clinical trials through payers who can identify diverse patient populations. So that's number 1.
Number 2, is not everybody has access to a clinical trial. There are limitations on where research is done, and we believe that payers can be the missing link in connecting patients who might be eligible to facilities that are actually running these clinical trials. There's a big gap in how many people actually have the opportunity to participate.
Those are where there's opportunities for patients. It's really in diversifying the clinical research and giving those populations that wouldn't necessarily have accessibility to those trials and then also just broadening the education and the awareness of clinical trials that are taking place in the market.
Andrew Cournoyer: On that education front, there might be one other thing that payers have an opportunity to support, because they have a large team of case management or case managers, or they are individuals who are making direct patient contact or out in the field. When it comes to a clinical trial, there's a lot of stigma associated with them that's kind of a treatment of last resort. And that's not usually the case, actually. It's getting someone involved earlier, like we were saying earlier, may actually drive a better outcome quicker soonere and then ultimately a better quality of life for that patient.
I think payers are in a unique position to help educate their members or patients, if you will, about the benefits of clinical trials to help remove some of the stigmas in the adoption. There are certainly a number of health disparities and social determinants of health that are negatively impacting the certain trust factors that go into patients entering into trials. And that might also be an opportunity for payers who have, in some cases, very broad reach to reach out and help remove some of those barriers.
Navigating Sport-Related Neurospine Injuries, Surgery, and Managed Care
February 25th 2025On this episode of Managed Care Cast, we speak with Arthur L. Jenkins III, MD, FACS, CEO of Jenkins NeuroSpine, to explore the intersection of advanced surgical care for sport-related neurospine injuries and managed care systems.
Listen
Varied Access: The Pharmacogenetic Testing Coverage Divide
February 18th 2025On this episode of Managed Care Cast, we speak with the author of a study published in the February 2025 issue of The American Journal of Managed Care® to uncover significant differences in coverage decisions for pharmacogenetic tests across major US health insurers.
Listen
How Access to SMA Treatment Varies Globally and by Insurance Type
March 18th 2025Posters presented at the 2025 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference show that therapeutic advances in treating spinal muscular atrophy (SMA) are not uniformly making it into the hands of patients who could benefit.
Read More
How Mirdametinib Improves QOL for People With NF1-Associated Plexiform Neurofibromas
March 18th 2025Christopher L. Moertel, MD, University of Minnesota, discusses the trial data that helped get mirdametinib approved and what providers can do to keep measuring quality of life (QOL) improvements.
Read More